Mizuho lowered the firm’s price target on Dentsply Sirona (XRAY) to $18 from $21 and keeps a Neutral rating on the shares following the investor conference. A key “make or break” dynamic for Dentsply in 2025 is the rate of uptake of its new Primescan 2 cloud-based intraoral scanner, and management has provided limited data on uptake so far, the analyst tells investors in a research note. The firm reduced estimates to reflect reflect slower growth.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XRAY:
- Dentsply Sirona downgraded to Hold from Buy at Needham
- Utah fluoride ban could be marginal tailwind to dental demand, says BofA
- Dentsply Sirona director buys $250K in common stock
- Hold Rating Maintained for DENTSPLY SIRONA Amid Market Challenges and Strategic Uncertainty
- DENTSPLY SIRONA’s Mixed Earnings Call Insights
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue